PR84724

SINGAPORE, July 9, 2020 /PRNewswire=KYODO JBN/ --

Study published in Infectious Disease and Therapy Journal

Mundipharma today announced that laboratory testing at the Duke-NUS Medical

School in Singapore, has confirmed the effectiveness of its BETADINE(R)

antiseptic products against the novel coronavirus (SARS-CoV-2) which causes

COVID-19 disease.

Logo - https://photos.prnasia.com/prnh/20200113/2689982-1LOGO

Testing has demonstrated BETADINE's(R) strong in-vitro virucidal activity,

killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to

testing were: BETADINE(R) antiseptic products, namely Solution (10% PVP-I),

Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray

(0.45% PVP-I).

The research has been published in the respected Infectious Disease and Therapy

Journal on 08 July 2020.

"These results confirm our view that BETADINE(R) antiseptic products, used

appropriately and in conjunction with other preventative treatment options

including PPE, can play a role in limiting the spread of infections, including

COVID-19," said Raman Singh, CEO Mundipharma.

"It also provides the medical community as well as consumers with a

science-based assurance that they are using a product that is a proven defence

against COVID-19," he added.

The study conducted at Duke-NUS is complemented by Laboratory testing completed

at the Tropical Infectious Diseases Research and Education Center (TIDREC) at

the University of Malaya, Malaysia, that also demonstrated strong in-vitro

virucidal activity, with the tested product BETADINE(R) Gargle and Mouthwash

(1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds. The TIDREC

research has been accepted by the British Dental Journal (BDJ) and was

published as a Letter on 26 June 2020. The journal is published by Springer

Nature on behalf of the British Dental Association.

Previously, BETADINE(R) antiseptic products containing povidone iodine (PVP-I)

have been proven effective in vitro against a wide range of viruses, including

coronaviruses that have caused major outbreaks such as Middle East Respiratory

Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE(R)

antiseptic range contains Povidone-iodine (PVP-I), which is highly effective

against a wide range of microorganisms, including bacteria, viruses and fungi

and is typically used in hospitals.

About Mundipharma

Mundipharma's independent associated companies are privately owned entities

covering the world's pharmaceutical markets. Mundipharma is a prime example of

a company that consistently delivers high-quality products while standing by

the values that represent the company. Our mission is to alleviate the

suffering of patients with cancer and non-cancer pain and to substantially

improve their quality of life. Mundipharma is dedicated to bringing to patients

with severe and debilitating diseases the benefit of novel treatment options in

fields such as pain, oncology, oncology supportive care, ophthalmology,

respiratory disease and consumer healthcare.

About BETADINE(R)

The BETADINE(R) range of products have been trusted by hospitals and consumers

around the world for over 60 years to prevent and treat infections.  Over the

last few years, Mundipharma has expanded the BETADINE(R) range of products to

include povidone-iodine and non-povidone iodine ranges for the prevention,

treatment and maintenance of a range of conditions from upper respiratory tract

infections, wound infections, feminine hygiene and infections and outbreaks to

personal and hand hygiene.  In-vitro and clinical studies have demonstrated

that BETADINE(R) povidone iodine kills a broad range of bacteria, viruses and

fungi including antibiotic-resistant strains.  

(R): BETADINE is a registered trademark of Mundipharma

For more information please visit: www.mundipharma.com.sg.

For further information please contact:

Email: media@mundipharma.com.sg

SOURCE         Mundipharma